|
KaloBios stock slides; to stop asthma study
MarketWatch KaloBios Pharmaceuticals Inc.'s (NASDAQ:KBIO) shares slumped after the company said it would discontinue development of a treatment for severe asthma, a move that followed disappointing Phase 2 results. Chief Executive Officer David Pritchard said … KaloBios Reports Top-Line Data for Phase 2 Study of KB003 in Severe Asthma … |
View full post on asthma – Google News